

A randomised double-blind trial comparing arimidex alone with nolvadex alone with arimidex and nolvadex in combination, as adjuvant treatment in post-menopausal women with breast cancer

Submission date 19/08/2002	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 19/08/2002	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 06/04/2017	Condition category Cancer	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

<http://cancerhelp.cancerresearchuk.org/trials/a-trial-comparing-anastrozole-and-tamoxifen-after-surgery-for-breast-cancer>

Contact information

Type(s)

Scientific

Contact name

Ms Joan Houghton

Contact details

ATAC secretariat
c/o Charles Bell House
67-73 Riding House Street
London
United Kingdom
W1W 7EJ
+44 20 3108 7288
j.houghton@ctg.ucl.ac.uk

Additional identifiers

Protocol serial number

ZEN1033IL/29

Study information

Scientific Title

A randomised double-blind trial comparing arimidex alone with nolvadex alone with arimidex and nolvadex in combination, as adjuvant treatment in post-menopausal women with breast cancer

Acronym

ATAC (Arimidex, Tamoxifen, Alone or in Combination)

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Breast cancer

Interventions

1. Group A: Arimidex (anastrozole) 1 mg plus Nolvadex (tamoxifen) placebo both daily for 5 years or until recurrence
2. Group B: Arimidex 1 mg plus Nolvadex 20 mg, both daily for 5 years or until recurrence
3. Group C: Arimidex placebo plus Nolvadex 20 mg, both daily for 5 years or until recurrence

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/12/1999

Eligibility

Key inclusion criteria

1. Histologically proven operable breast cancer
2. Patients must have completed primary surgery and chemotherapy (if given), and are candidates to receive hormonal adjuvant therapy
3. Deemed to be post-menopausal according to one of the following:
 - 3.1. Aged >60 years
 - 3.2. Bilateral oophorectomy
 - 3.3. Aged <60 years with a uterus and amenorrhoea for at least 12 months
 - 3.4. Aged <60 without a uterus and with follicle stimulating hormone (FSH) >20IU/L
4. No evidence of metastatic disease
5. If chemotherapy was started more than 8 weeks after primary surgery or chemotherapy was completed more than 8 weeks before randomisation the patients is excluded
6. No neo-adjuvant chemotherapy
7. Surgery must have been completed within 8 weeks prior to randomisation
8. No previous hormonal therapy as adjuvant treatment for breast cancer unless:
 - 8.1. Tamoxifen received prior to first surgical procedure for 28 days or less
 - 8.2. Hormonal therapy received pre-surgery in the context of a formal trial
9. Patients who have received tamoxifen as part of any breast cancer prevention trial are to be excluded
10. No previous malignancy within the last 10 years, except squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix, adequately cone biopsied
11. No treatment with a non-approved drug during the 3 months before randomisation
12. No medical contraindications to any of the treatments in the trial

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Key exclusion criteria

Does not match inclusion criteria

Date of first enrolment

01/01/1998

Date of final enrolment

01/12/1999

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

ATAC secretariat

London

United Kingdom

W1W 7EJ

Sponsor information

Organisation

AstraZeneca Clinical Research Group (UK)

ROR

<https://ror.org/04r9x1a08>

Funder(s)

Funder type

Industry

Funder Name

AstraZeneca Pharmaceuticals (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details

Date
created

Date
added

Peer
reviewed?

Patient-
facing?

Results article	results	01/01/2005	Yes	No
Results article	results of long-term safety analysis	01/08/2006	Yes	No
Results article	results on 10 year analysis of trial	23/11/2007	Yes	No
Results article	results of 100-month analysis	01/01/2008	Yes	No
Results article	five year results	01/03/2008	Yes	No
Results article	results on the effect of body mass index on recurrence rates	20/07/2010	Yes	No
Results article	results	01/12/2010	Yes	No
Results article	results	04/04/2012	Yes	No